Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: Clinical studies and practical approaches to therapy

International Journal of Clinical Practice

Volumn 66, Issue 12, 2012, Pages 1147-1157

  Tobin, G S ^a   Cavaghan, M K ^b   Hoogwerf, B J ^c   McGill, J B ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; ADJUVANT THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THYROID TUMOR; VOMITING;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VENOMS;

EID: 84869492009     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12032     Document Type: Review

References (53)

1. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35 (Suppl. 1): S11-63.
2. International Diabetes Federation. Treatment Algorithm for People with Type 2 Diabetes. 2011. Available from: http://www.idf.org/treatment-algorithm- people-type-2-diabetes (accessed September 2012).
3. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
4. Handelsman Y, Mechanick JI, Blonde L, et al., American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17 (Suppl. 2): 1-53.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
6. Turner RC, Cull CA, Frighi V, Holman RR,. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
7. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO,. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
8. Hermansen K, Davies M, Derezinski T, et al., A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-74.
9. Holman RR, Thorne KI, Farmer AJ, et al., Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30.
10. Riddle MC, Rosenstock J, Gerich J,. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
11. Rosenstock J, Davies M, Home PD, et al., A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-16.
12. Cryer PE,. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-48.
13. Hermansen K, Mortensen LS,. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-42.
14. Ismail-Beigi F, Moghissi E, Tiktin M, et al., Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011; 154: 554-9.
15. Genuth S, Ismail-Beigi F,. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab 2012; 97: 41-8.
16. Buse JB, Bergenstal RM, Glass LC, et al., Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-12.
17. Levin PA, Mersey JH, Zhou S, Bromberger LA,. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide In patients with type 2 diabetes. Endocr Pract 2011; 18: 17-25.
18. Thong KY, Jose B, Sukumar N, et al., Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13: 703-10.
19. Arnolds S, Dellweg S, Clair J, et al., Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-15.
20. Nayak UA, Govindan J, Baskar V, et al., Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010; 103: 687-94.
21. Yoon NM, Cavaghan MK, Brunelle RL, Roach P,. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31: 1511-23.
22. Sheffield CA, Kane MP, Busch RS, et al., Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008; 14: 285-92.
23. John LE, Kane MP, Busch RS, Hamilton RA,. Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 2007; 20: 59-63.
24. Viswanathan P, Chaudhuri A, Bhatia R, et al., Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13: 444-50.
25. Kendall DM, Cuddihy RM, Bergenstal RM,. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur J Intern Med 2009; 20 (Suppl. 2): S329-39.
26. Defronzo RA,. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
27. Drucker DJ,. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
28. Kolterman OG, Buse JB, Fineman MS, et al., Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-9.
29. Kolterman OG, Kim DD, Shen L, et al., Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-81.
30. Cervera A, Wajcberg E, Sriwijitkamol A, et al., Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294: E846-52.
31. Cersosimo E, Gastaldelli A, Cervera A, et al., Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab 2011; 96: 1763-70.
32. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc., 2011.
33. Bunck MC, Corner A, Eliasson B, et al., One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212: 223-9.
34. Heine RJ, Van Gaal LF, Johns D, et al., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-69.
35. Macconell L, Brown C, Gurney K, Han J,. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012; 5: 29-41.
36. Ryder REJ, Thong KY, Cull ML, et al., The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Practical Diabetes International 2010; 27: 352-7.
37. Davies MJ, Donnelly R, Barnett AH, et al., Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153-62.
38. Barnett AH, Burger J, Johns D, et al., Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-48.
39. Monnier L, Lapinski H, Colette C,. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5.
40. Rosenstock J, Shenouda SK, Bergenstal RM, et al., Baseline factors associated with glycemic control and weight loss when exenatide twice daily Is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012; 35: 955-8.
41. Gerstein HC, Yale JF, Harris SB, et al., A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-42.
42. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al., Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-51.
43. Raskin P, Allen E, Hollander P, et al., Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
44. Buse JB, Henry RR, Han J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
45. DeFronzo RA, Ratner RE, Han J, et al., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.
46. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
47. Moretto TJ, Milton DR, Ridge TD, et al., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-60.
48. Zinman B, Hoogwerf BJ, Duran Garcia S, et al., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-85.
49. Victoza [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S, 2011.
50. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc., 2012.
51. Barnett AH, Charbonnel B, Donovan M, et al., Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28: 513-23.
52. Fonseca V, Schweizer A, Albrecht D, et al., Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diab tologia 2007; 50: 1148-55.
53. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al., Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167-77.